SEC Form 4 · accession 0000908662-15-000284
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul J Mellett
Officer — Treasurer and CFO
Period of report
Aug 7, 2015
Accepted (ET)
Aug 10, 2015 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 7, 2015 | S | 6,200 | $42.6031 | D | 76,697 | D | |
| Common StockF3 | Aug 7, 2015 | S | 1,100 | $43.8009 | D | 75,597 | D | |
| Common StockF4 | Aug 7, 2015 | S | 200 | $45.345 | D | 75,397 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2015 to provide liquidity for tax payments due on account of prior option exercises.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.2100 to $43.0300, inclusive.
- F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.6700 to $44.2000, inclusive.
- F4The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.2100 to $45.4800, inclusive.
Remarks
The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4 above.